Despite its importance in the fight against pandemics such as COVID-19, a lesser-known face of nanomedicine is its potential to contribute to solutions to so-called rare or minority diseases. Coinciding with February 28th, the world day for rare diseases, experts invited by the Nanomed Spain platform and the Sant Joan de Déu Research Institute (IRSJD) present the latest advances in nanomedicine against three of these disorders: muscular dystrophy, cystic fibrosis and Fabry disease.
Researchers from the Institute for Bioengineering of Catalonia (IBEC), led by Eduard Torrents, leader of the group “bacterial infections and antimicrobial therapies” and professor at the University of Barcelona (UB), in collaboration with Josep Samitier, principal investigator of the group “Nanobioingineering” of IBEC, and Maite Martin, of the Vall d’Hebron Barcelona Hospital appear in the media for the new device, called BiofilmChip, which allows a custom and precise diagnosis of chronic infections.
IBEC researchers develop a device that allows to grow biofilms and analyze their susceptibility to different antibiotics in a simple way and using patient samples. BiofilmChip, a low-cost, easy-to-use diagnostic device, opens the way to finding effective and custom treatments against chronic infections produced by biofilms.
A comprehensive review led by IBEC researchers from the “Bacterial infections: antimicrobial therapies” group highlights the clinical relevance of the bacterium Pseudomonas aeruginosa and its presence in bacterial biofilms.
A new study by IBEC’s Bacterial Infections: Antimicrobial Therapies and Molecular and cellular neurobiotechnology groups shows that Galleria mellonella larvae can be effective to test the toxicity of nanoparticles. This work thus paves the way toward a new animal model for toxicity studies that represent an inexpensive and more ethical alternative to rodent testing.
Eduard Torrents, group leader at IBEC is interviewed in the radio program “Després del Col·lapse” of RTVE talking about his research on new therapies for infectious diseases in the face of antibiotic resistance.